Event

Mark Labadia

PhD
Boehringer Ingelheim Pharmaceuticals, Inc.

U Biopred Study Group

PhD
BioSci Consulting

David Lamb

PhD
Boehringer Ingelheim Pharma GmbH & Co. KG

Michael Könen-Bergmann

PhD
Boehringer Ingelheim Pharma GmbH & Co. KG

Denis Delic

PhD
Boehringer Ingelheim Pharma GmbH & Co. KG

Jonas Erjefält

PhD
Lund Univ

Caroline Sandén

PhD
Medetect AB

Hans Jürgen Hoffmann

BSc(Hons), PhD
Aarhus University

Verena Brauchle

BSc
Boehringer Ingelheim Pharma GmbH & Co. KG

Eva Thaler

BSc
Boehringer Ingelheim Pharma GmbH & Co. KG

Sylvia Blum

BSc
Boehringer Ingelheim Pharma GmbH & Co. KG

Martina Keck

BSc
Boehringer Ingelheim Pharma GmbH & Co. KG

Ingrid Christ

BSc
Boehringer Ingelheim Pharma GmbH & Co. KG

Karsten Quast

PhD
Boehringer Ingelheim Pharma GmbH & Co. KG

Armin Braun

Prof. Dr. rer. nat.
Fraunhofer ITEM;Fraunhofer ITEM, Biomedical Research in Endstage and Obstructive Lung (BREATH), Member of the German;Fraunhofer ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hanno

Katrin Fundel-Clemens

PhD
Boehringer Ingelheim Pharma GmbH & Co. KG

Dorothy De Sousa

PhD
Boehringer Ingelheim (Canada) Ltd./Ltée

Katherina Sewald

Dr. rer. nat.
Fraunhofer ITEM;Fraunhofer ITEM, Biomedical Research in Endstage and Obstructive Lung (BREATH), Member of the German;Fraunhofer ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hanno

Joseph Wahle

PhD
Boehringer Ingelheim Pharmaceuticals, Inc.

The Potential for RORgamma Antagonists to Treat A Sub-Population of Severe Asthma: A Translational Approach